ArticleHepatology international2022
Long-term cardiovascular outcomes differ across metabolic dysfunction-associated fatty liver disease subtypes among middle-aged population.
Article in Hepatology international, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 36 citations in OpenAlex.
- The Influence of Metabolic Dysfunction-Associated Steatotic Liver Disease and Body Mass Index on the Incidence of Alzheimer Disease: A Nationwide Cohort Study.Gut and liver · 2026Article
- Non-lean versus lean MASLD: associations with advanced cardiovascular-kidney-metabolic syndrome in adults with type 2 diabetes mellitus, a cross-sectional study.Frontiers in endocrinology · 2026Article
- Association between metabolic dysfunction-associated steatotic liver disease and heart failure with preserved ejection fraction.Przeglad gastroenterologiczny · 2026Review
- Association Between Thyroid Function Indicators and Metabolic-Associated Fatty Liver Disease: Effect Modification by Iodine Nutritional Status.International journal of endocrinology · 2026Article
- Associations between metabolic dysfunction-associated fatty liver disease and carotid and femoral atherosclerosis: a population-based cross-sectional study.Lipids in health and disease · 2025Article
- Metabolic dysfunction-associated steatotic liver disease and its associated health risks.Journal of the Chinese Medical Association : JCMA · 2025Review
- Association Between Handgrip Strength and Cardiovascular Disease Risk in MASLD: A Prospective Study From UK Biobank.Journal of cachexia, sarcopenia and muscle · 2025Article
- Metabolic Dysfunction Associated-Steatotic Liver Disease (MASLD) and Cardiovascular Risk: Embrace All Facets of the Disease.Current cardiology reports · 2025Review
- The relationship between MAFLD and CVD in a health check-up Chinese population: a prospective cohort study.Therapeutic advances in chronic disease · 2025Article
- The association between phenotypes of polycystic ovary syndrome and metabolic dysfunction-associated fatty liver disease.Frontiers in endocrinology · 2025Article
- Association of nonalcoholic fatty liver disease with new-onset atrial fibrillation stratified by age groups.Cardiovascular diabetology · 2024Article
- Metabolic dysfunction-associated fatty liver disease and heavy alcohol consumption increase mortality:A nationwide study.Hepatology international · 2024Article
- Comparison of SGLT2 inhibitors vs. DPP4 inhibitors for patients with metabolic dysfunction associated fatty liver disease and diabetes mellitus.Journal of endocrinological investigation · 2024Article
- Genome-wide association study of metabolic dysfunction-associated fatty liver disease in a Korean population.Scientific reports · 2024Article
- MAFLD: an ideal framework for understanding disease phenotype in individuals of normal weight.Therapeutic advances in endocrinology and metabolism · 2024Review
- Association of Metabolic Dysfunction-Associated Fatty Liver Disease With Risk of HF and AF.JACC. Asia · 2023Article
- Differential risk of 23 site-specific incident cancers and cancer-related mortality among patients with metabolic dysfunction-associated fatty liver disease: a population-based cohort study with 9.7 million Korean subjects.Cancer communications (London, England) · 2023Article
- Transition patterns of metabolic dysfunction-associated fatty liver disease status in relation to arterial stiffness progression: a health check-up cohort study.Scientific reports · 2023Article
- NAFLD, MAFLD, and beyond: one or several acronyms for better comprehension and patient care.Internal and emergency medicine · 2023Review
- From NAFLD to MAFLD: Definition, Pathophysiological Basis and Cardiovascular Implications.Biomedicines · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
BACKGROUND AND
aimsThe new metabolic dysfunction-associated fatty liver disease (MAFLD) criteria include the following three distinct subtypes: MAFLD with diabetes mellitus (DM), overweight/obese (OW), or lean/normal weight with metabolic dysfunction. We investigated whether long-term cardiovascular disease outcomes differ across the MAFLD subtypes.
methodsFrom a nationwide health screening database, we included 8,412,730 participants (48.6% males) aged 40-64 years, free of cardiovascular disease history, between 2009 and 2010. Participants were categorized into non-MAFLD, OW-MAFLD, lean-MAFLD, and DM-MAFLD. The primary outcome was a composite cardiovascular disease event, including myocardial infarction, ischemic stroke, heart failure, or cardiovascular disease-related death. The presence of advanced liver fibrosis was estimated using a BARD score ≥ 2.
resultsAmong the study participants, 3,087,640 (36.7%) had MAFLD, among which 2,424,086 (78.5%), 170,761 (5.5%), and 492,793 (16.0%) had OW-MAFLD, lean-MAFLD, and DM-MAFLD, respectively. Over a median follow-up period of 10.0 years, 169,433 new cardiovascular disease events occurred. With the non-MAFLD group as reference, multivariable-adjusted hazard ratios (95% confidence intervals) for cardiovascular disease events were 1.16 (1.15-1.18), 1.23 (1.20-1.27), and 1.82 (1.80-1.85) in the OW-MAFLD, lean-MAFLD, and DM-MAFLD groups, respectively. Participants with lean-MAFLD or DM-MAFLD had a higher cardiovascular disease risk than those with OW-MAFLD, irrespective of metabolic abnormalities or comorbidities. The presence of advanced liver fibrosis was significantly associated with a higher cardiovascular disease risk in each MAFLD subtype.
conclusionLong-term cardiovascular disease outcomes differed across the MAFLD subtypes. Further studies are required to investigate whether preventive or therapeutic interventions should be optimized according to the MAFLD subtypes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.